Search
Gamolenic acid
go.drugbank.com/drugs/DB13854ApprovedWithdrawnGamolenic acid, or gamma-linolenic acid (γ-Linolenic acid) or GLA, is an essential fatty acid (EFA) comprised of 18 carbon atoms with three double bonds [F27] that is most commonly found in human milk … While Gamolenic acid is found naturally in the fatty acid fractions of some plant seed oils [F27], [DB11358] and [DB11238] are rich sources of gamolenic acid.
Synonyms: 18:3 (n-6)Glycocholic acid
go.drugbank.com/drugs/DB02691InvestigationalThe glycine conjugate of cholic acid. It acts as a detergent to solubilize fats for absorption and is itself absorbed.
Synonyms: N-choloylglycineCategories: Compounds used in a research, industrial, or household setting, N-substituted GlycinesInfluenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB21765ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes.
Influenza A virus A/West Virginia/30/2022 (H1N1) Recombinant Hemagglutinin Antigen
go.drugbank.com/drugs/DB17995ApprovedWithdrawnRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes.
Influenza A virus A/Georgia/12/2022 CVR-167 (H1N1) Antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB17996ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes.
Influenza A virus A/Victoria/4897/2022 IVR-238 (H1N1) Antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB17998ApprovedWithdrawnRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes.
Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen
go.drugbank.com/drugs/DB18661ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes.
Influenza A virus A/Sydney/1304/2022 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB19321ApprovedRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes.
Influenza A virus A/Massachusetts/18/2022 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB19322ApprovedWithdrawnRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes.
Influenza A virus A/Thailand/8/2022 IVR-237 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB19323ApprovedWithdrawnRecombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes.